On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B Patients

Wong, Grace Lai–Hung; Wong, Vincent Wai‐Sun; Choi, Paul Cheung–Lung; Chan, Anthony Wing–Hung; Chim, Angel Mei‐Ling; Yiu, Karen; Chu, Shumo; Chan, Francis K.L.; Sung, Joseph J.Y.; Chan, Henry Lik‐Yuen

doi:10.3851/imp1726

Cited by 87 publications

(87 citation statements)

References 29 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, high ALT level contributes to increased liver stiffness. After ALT normalization with antiviral therapy, the liver stiffness typically declines even without regression of fibrosis [86]. Whether the on-treatment liver stiffness remains robust in prognostication is currently unclear.…”

Section: Diagnosis Of Cirrhosis As the Achilles Heelmentioning

confidence: 98%

Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?

Wong

Janssen

2015

Journal of Hepatology

Self Cite

104

111

View full text Add to dashboard Cite

Chronic hepatitis B is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Accurate prediction of HCC risk is important for decisions on antiviral therapy and HCC surveillance. In the last few years, a number of Asian groups have derived and validated several HCC risk scores based on well-known risk factors such as cirrhosis, age, male sex and high viral load. Overall, these scores have high negative predictive values of over 95% in excluding HCC development in 3 to 10 years. The REACH-B score was derived from a community cohort of non-cirrhotic patients and is better applied in the primary care setting. In contrast, the GAG-HCC and CU-HCC scores were derived from hospital cohorts and include cirrhosis as a major integral component. While the latter scores may be more applicable to patients at specialist clinics, the diagnosis of cirrhosis based on routine imaging and clinical parameters can be inaccurate. To this end, recent developments in non-invasive tests of liver fibrosis may further refine the risk prediction. The application of HCC risk scores in patients on antiviral therapy and in other ethnic groups should be evaluated in future studies.

show abstract

Section: Diagnosis Of Cirrhosis As the Achilles Heelmentioning

confidence: 98%

Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?

Wong

Janssen

2015

Journal of Hepatology

Self Cite

104

111

View full text Add to dashboard Cite

show abstract

“…This may be due to the fact that patients without liver cirrhosis had a better liver condition than those in group 1 when they were enrolled and their hepatic histological changes are based on necroinflammation. Wong et al (15) prospectively studied patients with CHB undergoing liver biopsy twice before and at week 48 of antiviral treatment, revealing a significant decrease of the metavir fibrosis score, while the metavir activity score showed no significant change.…”

Section: Discussionmentioning

confidence: 99%

Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B

Jin

Zhang

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Significant histologic improvements have been documented in studies of paired liver biopsies from patients with chronic hepatitis C who achieved sustained viral eradication (Poynard et al 2002;Shiratori et al 2000) and patients with chronic hepatitis B who received long-term antiviral therapy (Chang et al 2010;Hadziyannis et al 2006). Several studies reported a significant decrease in liver stiffness values, compared with baseline values, in patients with HCV who achieved sustained viral eradication (Fontana et al 2009;Hezode et al 2011;Martinez et al 2011b;Ogawa et al 2009;Vergniol et al 2009;Stasi et al 2013;Casado et al 2013), as well as in HBV-infected patients treated with nucleoside analog drugs (Enomoto et al 2010;Fung et al 2011b;Lim et al 2011;Ogawa et al 2011;Osakabe et al 2011;Wong et al 2011;Kim et al 2013;Kuo et al 2014).…”

mentioning

confidence: 93%

WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 3: Liver

Barr

Nakashima

Amy

et al. 2015

Ultrasound in Medicine & Biology

684

577

View full text Add to dashboard Cite

The World Federation for Ultrasound in Medicine and Biology (WFUMB) has produced these guidelines for the use of elastography techniques in liver disease. For each available technique, the reproducibility, results, and limitations are analyzed, and recommendations are given. Finally, recommendations based on the international literature and the findings of the WFUMB expert group are established as answers to common questions. The document has a clinical perspective and is aimed at assessing the usefulness of elastography in the management of liver diseases.

show abstract

On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B Patients

Abstract: LSM could predict advanced fibrosis during antiviral therapy according to the ALT-based algorithm. Decrease in absolute LSM value, which could be related to ALT normalization, was unreliable to indicate regression of liver fibrosis.

Cited by 87 publications

References 29 publications

Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?

Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?

Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B

WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 3: Liver

Contact Info

Product

Resources

About